Chapter from the book *Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways*

Downloaded from: http://www.intechopen.com/books/breast-cancer-carcinogenesis-cell-growth-and-signalling-pathways

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Lipid Rafts as Master Regulators of Breast Cancer Cell Function

Irina S. Babina¹, Simona Donatello¹, Ivan R. Nabi² and Ann M. Hopkins¹

¹Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin
²University of British Columbia, Vancouver
¹Ireland
²Canada

1. Introduction

Cancer is a leading cause of death in developed countries, and is on the rise in developing countries due in part to a lack of prophylactic screening and non-universal access to medical care (Jemal et al., 2011). Breast cancer is initiated when breast epithelial cells escape growth arrest and form a proliferating tumour mass. Numerous cellular mechanisms are dysregulated in breast tumour cells, including modified cell fate, altered protein signalling and trafficking, and enhanced cell migratory potential. Although these events are complex and subject to regulation by multiple elements, recent evidence has suggested that specialised cell membrane domains termed lipid rafts are actively involved in each of these processes (Cary & Cooper, 2000; Nabi & Le, 2003; Simons & Toomre, 2000). This chapter will therefore focus on the contribution of lipid rafts to breast cancer initiation and progression under these headings.

Lipid rafts are sub-domains of the cell membrane enriched in cholesterol and glycosphingolipids (Le Moyec et al., 1992; Nohara et al., 1998). These microdomains cluster together proteins involved in the regulation of crucial cellular processes; many of which are altered in cancer cells (Pike, 2003; de Laurentiis et al., 2007). Furthermore, lipid rafts are readily modified by diet and nutrition (Schley et al., 2007; Yaqoob, 2009), and studies have shown that fatty acid supplementation sensitises human mammary tumour cells to the cytotoxic effects of anti-cancer agents in vitro and in vivo (Germain et al., 1998; Menendez et al., 2005; Colas et al., 2006). This chapter will focus on the potential regulatory functions of lipid rafts as a novel approach towards understanding mechanisms of cancer initiation, progression and cell migration, a key event preceding metastatic progression. Finally it will discuss the potential of lipid rafts as novel therapeutic targets in breast cancer.

2. What are lipid rafts?

The discovery of glycosphingolipid clustering in the Golgi apparatus and at the apical surface of polarised epithelial cells led to the hypothesis of non-random membrane compartmentalisation (Simons & Ikonen, 1997; van Meer et al., 2008). These “compartments” were termed lipid rafts.
The structure and function of lipid raft domains depend on their lipid and protein compositions. An example of this is the sub-population of lipid rafts first identified in endothelial cells as flask-shaped membrane invaginations termed caveolae, or “little caves” (Yamada, 1955), which subsequent characterisation revealed to be enriched in proteins from the caveolin family (Rothberg, K G et al., 1992). Caveolins localise in the cytoplasmic leaflet of the cell membrane, and, together with high concentrations of cholesterol, are responsible for the characteristic curvature of caveolar membranes. Lipid rafts and caveolae have different structural protein markers and different proteins associated with them (Table 1), but their lipid composition and the mechanisms of protein targeting to them are very similar.

| Lipids                      | Protein Markers | Receptor Proteins | Signalling Proteins | References                             |
|-----------------------------|-----------------|-------------------|---------------------|----------------------------------------|
| **Non-caveolar lipid rafts**|                 |                   |                     |                                        |
| Cholesterol                | Flotillin-1, -2 | Fas, EGFR, HER2, IGF-1R, CD44, ER | Ras, Src, Erk2, Shc | (Nohara et al., 1998; de Laurentiis et al., 2007; Patra, 2008) |
| Glycosphingolipid          |                 |                   |                     |                                        |
| Sphingomyelin               |                 |                   |                     |                                        |
| Ganglioside GM1             |                 |                   |                     |                                        |
| Ganglioside GM3             |                 |                   |                     |                                        |
| **Caveolae**                |                 |                   |                     |                                        |
| Cholesterol                | Caveolin-1, -2 and -3 | Ras, Src, eNOS, PI3 kinase, Phospholipase C |                     |                                        |
| Glycosphingolipid          |                 |                   |                     |                                        |
| Sphingomyelin               |                 |                   |                     |                                        |
| Ganglioside GM1             |                 |                   |                     |                                        |

Table 1. Lipid and protein contents of caveolae and non-caveolar lipid rafts.

2.1 Lipid composition of membrane rafts
The functional properties of raft sub-populations differ according to subtle variations in the types of lipid and quantities of cholesterol they contain. This has permitted differential detergent extraction of various types of lipid rafts. The cholesterol concentration in detergent-resistant membranes (rafts) is 3-5 times higher than that in total membranes (Brown & Rose, 1992; Pike & Casey, 2002), sphingomyelin represents 10-15% of total lipid content, while glycosphingolipids such as cerebrosides and gangliosides account for a further 10-20% (Brown & Rose, 1992; Prinetti et al., 2000). In contrast, glycerophospholipids (including membrane phospholipids) comprise less than 30% of raft lipids despite accounting for approximately 60% of total membrane lipids (Brown & Rose, 1992; Pike & Casey, 2002). Raft-enriched lipids localise preferentially on the outer leaflet of the cell membrane, unlike glycerophospholipids (Pike, 2003). These observations suggest that lipid rafts are bilayer structures and that a variable composition of the cell membrane leaflets may play a role in recruitment of various proteins into lipid rafts. Accordingly, proteins can be targeted to rafts in many dynamically-regulated ways, including attachment of glycosylphosphatidylinositol (GPI) anchors or via lipid modifications such as prenylation and palmitoylation.
2.2 Protein targeting to lipid rafts

Perhaps the best-characterised system of protein association with lipid rafts is via modification with GPI anchors. The GPI anchor is a conserved oligosaccharide core covalently linked to a lipid moiety embedded in the outer leaflet of the cell membrane through acyl or alkyl chains (Levental et al., 2010). These anchors are added to soluble polypeptides in the lumen of the endoplasmic reticulum (ER), promoting membrane raft affiliation (Brown & Rose, 1992). Partitioning of GPI-anchored proteins into lipid rafts may allow sorting to the apical surface of polarised epithelial cells (Fiedler et al., 1993).

Another way in which proteins are targeted to lipid rafts is through addition of prenyl groups. Two types of prenyl groups, C\textsubscript{15} farnesyl and C\textsubscript{20} geranylgeranyl, are added on to C-terminal cysteine-rich domains of cytoplasmic proteins by prenyl transferases (Casey & Seabra, 1996). Although prenylated proteins are reportedly enriched in lipid rafts (Prior & Hancock, 2001; Parmryd et al., 2003), it is thought that the prenyl groups interact with raft-associated proteins rather than being directly incorporated into rafts (Magee & Seabra, 2003).

Another lipid post-translational modification, palmitoylation, is dynamically regulated by enzymes (Kang et al., 2008; Wan et al., 2007), and controls raft targeting of certain proteins in physiological and pathophysiological settings. Palmitoylation involves the addition of palmitic acid moieties to integral and peripheral membrane proteins through esterification (Bhatnagar & Gordon, 1997). Membrane-associated palmitoyl acyltransferases (PATs) are the most studied palmitoylation enzymes (Planey & Zacharias, 2009), while the palmitoyl thioesterase family removes palmitate groups (Camp & Hofmann, 1995). Close proximity of protein cysteine residues to the membrane is thought to facilitate palmitoylation by PATs, whereas membrane-distal residues are more likely to be prenylated or N-myristoylated (Bijlmakers & Marsh, 2003). PAT activity has been linked to lipid rafts (Dunphy et al., 2001), with palmitoylated proteins found either at the cell membrane or on intracellular membranes (Lobo et al., 2002; Roth et al., 2002). Palmitoylated proteins are naturally more lipophilic, thus their affinity for lipid rafts is increased. Many proteins are targeted to lipid rafts through palmitoylation, including flotillins, Src family kinases, endothelial nitric oxide synthase and various transmembrane receptors (Ghosh et al., 1998; Gong et al., 2003).

2.2.1 Flotillin-1 and -2 mark non-caveolar lipid rafts

Non-caveolar lipid rafts are associated with expression of the reggie family of proteins, flotillin-1 and flotillin-2 (Figure 1a). Palmitoylation of flotillin-1 is essential for localisation to lipid rafts (Morrow et al., 2002), while two hydrophobic stretches also contribute to its raft affiliation (Liu et al., 2005). On the other hand, flotillin-2 is raft-targeted via both myristoylation and palmitoylation. Flotillins were originally thought to be localised in caveolae (Bickel et al., 1997), however later studies excluded this (Neumann-Giesen et al., 2004; Stuermer et al., 2004). Much remains to be determined about the functionality of flotillins in lipid rafts, in particular, the significance of their highly conserved N-terminal domain (Babuke & Tikkanen, 2007; Tavernarakis et al., 1999).

2.2.2 Caveolins – selective markers for caveolar lipid rafts

Along with glycosphingolipids (Tran et al., 1987) and increased cholesterol (Rothberg, K. G. et al., 1990), caveolae are enriched in the family of 21-24 kDa integral membrane proteins known as caveolins. There are three known caveolins: caveolin-1 (Rothberg, J. M. & Artavanis-Tsakonas, 1992), caveolin-2 (Okamoto et al., 1998) and caveolin-3 (Tang et al., 1996).
Caveolins form “omega” structures in the membrane via cytoplasmic localization of both their N- and C-termini (Figure 1b). Aside from palmitoylation, the ability of caveolins to bind sphingolipids (Fra et al., 1995) and cholesterol (Murata et al., 1995) can also explain their high affinity for caveolar lipid rafts. Caveolins -1 and -2 are abundantly expressed in most cell types, including adipocytes, fibroblasts, endothelial and epithelial cells (Fan et al., 1983; Galbiati et al., 2001). Caveolin-3 expression however is restricted to muscle (Rubin et al., 2007). The N-terminal region of caveolin-1 contains a scaffolding domain which aids interactions with various signalling molecules, illustrating the potential importance of caveolin-1 for the signalling functions of caveolar lipid rafts (Everson & Smart, 2006).

### 2.3 Physiological functions of lipid rafts

Lipid rafts and caveolae are often viewed as organisation centres or signalling platforms, and Table 1 outlines examples of raft-associated proteins which will be discussed in the text. In this chapter, we will concentrate on dynamic raft regulation of a variety of physiological processes, including membrane trafficking, cell polarisation and signal transduction.

#### 2.3.1 Membrane trafficking and cell polarity

Membrane trafficking allows exchange of cellular components between cell sites and cellular organelles. In polarised epithelial cells the trafficking machinery is highly polarised, targeting plasma membrane proteins to separate apical and basolateral domains (Mellman & Nelson, 2008). Following lipid and protein synthesis in the ER, vesicular transfer mediates transport to subsequent or final destinations (Rodriguez-Boulan et al., 2005). The formation and distribution of vesicles requires organised stabilisation of the membrane to allow...
deformation and fusion with the target compartment. The most studied mechanism involves coating of the vesicle with clathrin oligomers (Gorelick & Shugrue, 2001), which is thought to be vital in basolateral protein sorting (Deborde et al., 2008; Folsch et al., 2009). Apical trafficking is less understood, but lipid rafts have been proposed to play a decisive role (Schuck & Simons, 2004). Conformational changes in the membrane are proposed to occur via oligomerisation and fusion of many small lipid raft domains (Lipowsky, 1993). Attachment of GPI anchors may also contribute to the polarisation of membrane trafficking (Paladino et al., 2008).

2.3.2 Cell signalling
Lipid raft-mediated trafficking of lipids and proteins facilitates dynamic regulation of cellular signalling cascades. Several frameworks have been suggested to link rafts to signal transduction. The simplest interpretation views lipid rafts as platforms where signalling molecules are co-localised, aiding their structural interactions and influencing downstream signalling (Lingwood et al., 2009). The nature of a signal may be modified by the type of lipid raft the target molecule is localised in and also the primary location of the raft, which in turn enhances the specificity of the signal. Rafts can also control cellular signalling by altering the function of their affiliated proteins. Accumulating evidence suggests that raft-associated proteins behave differently whether localized inside or outside of rafts. Modified signal transduction following lipid raft/caveolar disruption has been reported in the case of several signalling cascades involving Erk (Furuchi & Anderson, 1998), EGFR (Rengerike et al., 2002; Schley et al., 2007), insulin receptor (Parpal et al., 2001), and PDGF receptor (McGuire et al., 1993).

Finally, some lipid rafts are actively involved in endocytosis (reviewed in Lajoie & Nabi, 2010), which promotes internalisation of receptors and signalling molecules. This process may be facilitated by clustering of caveolin or receptor proteins (Paladino et al., 2004). Internalisation of ligands or receptors modifies downstream signal transduction, and is associated with the termination of extracellular ligand-driven signalling events via transient receptor desensitisation.

The ability of lipid rafts to traffic proteins, control cell polarity and alter cell signalling underlies their emerging roles as crucial regulators of cellular processes including cell fate, growth, adhesion and migration. Since all are dysregulated in cancer, it is reasonable to suggest that lipid rafts may modify tumorigenic processes. This will next be addressed.

3. Lipid raft regulation of key processes in breast cancer cells
Alterations in cell fate, growth, adhesion and migration play central roles in the initiation and progression of breast cancer. We next outline how lipid rafts may regulate such processes during the initial stages of cancer development, during tumour growth and during the possible progression to a migratory and metastatic phenotype.

3.1 Apoptosis and regulation of cell fate
Defects in apoptosis allow tumour cells to escape growth-inhibitory signals and to progress through the cell cycle. Two major apoptotic pathways have been described, extrinsic (mediated by activation of death receptors) and intrinsic (mediated by mitochondria). Both may require lipid rafts for successful signal transduction (Li et al., 1998).
Death receptors are located at the cell membrane, and once activated, trigger apoptotic signal transduction. Perhaps the best-characterised death receptor is Fas (CD95 or APO-1), which has been implicated in the apoptotic events that drive physiological remodelling of the mammary gland after breast feeding (Song et al., 2000). Down-regulation of Fas has also been associated with poor prognosis in breast cancer patients (Reimer et al., 2000), and inhibition of Fas activity has been linked to drug resistance (Landowski et al., 1997). Activation of Fas results in receptor aggregation, and recruitment of procaspase-8 to form the death-inducing signalling complex DISC (Peter & Krammer, 2003) (Figure 3a). Recent studies have shown that Fas is translocated into lipid rafts, where apoptotic receptor aggregation takes place (Gajate et al., 2004; Gajate & Mollinedo, 2005). This is the mode of action of a pro-apoptotic drug, edelfosine; with cholesterol depletion being shown to abolish apoptosis (Gajate & Mollinedo, 2001; Gajate & Mollinedo, 2007; Gajate et al., 2009).

Whether rafts could be used as targets to re-trigger Fas-dependent apoptosis in tumour cells is an intriguing concept. A recent study demonstrated that nitric oxide (NO) can reverse apoptotic resistance via increasing Fas S-nitrosylation (Leon et al., 2011). In breast cancer cells that overexpressed wild-type Fas, NO incubation resulted in enhanced recruitment of the receptor into lipid rafts, which in turn sensitized cancer cells to the death-inducing Fas ligand. In fact, DISC formation is impaired in cells expressing nitrosylation (Leon et al., 2011) and palmitoylation (Chakrabandhu et al., 2007) mutants of Fas.

Acquired resistance of breast cancer cells to Fas-induced apoptosis may alternatively result from activation of survival pathways, such as the PI3 kinase pathway. Its engagement leads to activation of the serine-threonine kinase Akt, which negatively regulates apoptosis by inactivating pro-apoptotic proteins such as Bad and caspase-9 (Datta et al., 1999). Lipid raft localisation of Akt has been implicated in facilitating its activation (Hill et al., 2002; Elhyany et al., 2004). Raft disruption has been reported to reduce the sensitivity of normal-like MCF-10a cells to apoptosis, suggesting that tumour cells rely on cholesterol for growth and malignant signalling (Li et al., 2006). Interestingly the cholesterol analogue ginsenoside Rh2 has been shown to reduce lipid raft abundance and increase internalisation, decreasing Akt-dependent survival signalling (Park et al., 2010). It has also been demonstrated that cholesterol depletion induces anoikis-like apoptosis via down-regulation of focal adhesion kinase and hypoxia inducible factor-1 (Lee et al., 2009; Park et al., 2009).

Another apoptotic death receptor is TNF-related apoptosis-inducing ligand (TRAIL) receptor 1 and 2, referred to as DR4 and DR5 respectively (Yang et al., 2010). Studies have demonstrated that translocation of these receptors into lipid rafts after TRAIL engagement is involved in apoptotic signal transduction (Merino et al., 2006; Dumitru et al., 2007; Song et al., 2007). In metastatic MDA-MB-231 cells, for instance, DR4 palmitoylation (Rossin et al., 2009) is crucial not only for its localisation into lipid rafts but also for receptor aggregation, both of which are essential for TRAIL-induced cell death (Merino et al., 2006). Therefore while much remains to be understood about the role of rafts in regulating apoptosis in breast cancer cells, it may offer a novel therapeutic target (see Section 4).

3.2 Growth and metabolism

In conjunction with altered apoptosis, abnormal signalling by growth factor receptors can facilitate breast tumour proliferation and growth. Lipid rafts modulate the signalling functions of several growth factor receptors, including the ErbB (HER) family of receptors.
Fig. 2. Lipid raft regulation of breast cancer cell processes. (A.) Apoptotic signals are transduced via lipid rafts. (B.) EGFR signalling may induce apoptosis (1.) or proliferation (2.) outside of lipid rafts. Predominant oncogenic signalling is transduced through rafts (3.). (C.) Rafts cluster many degradation enzymes and proteins crucial for cell migration.
ErbB receptors are often mutated, amplified and/or overexpressed in breast cancer (Troyer & Lee, 2001). In particular, epidermal growth factor receptor, EGFR, and HER2 homo- and heterodimerisations have been described to promote oncogenic proliferation (Barros et al., 2010). Both of these receptors are associated with lipid rafts, and raft modifications can alter their signal transduction (Chen & Resh, 2002; Freeman et al., 2007).

EGFR functionality in particular is largely dependent upon its affiliation with rafts. Upon ligand binding, EGFR translocates out of caveolin-positive raft domains to stimulate downstream signalling (Mineo et al., 1999) and caveolin-1 raft domains negatively regulate EGFR activation (Lajoie et al., 2007). Accordingly, raft disruption via cholesterol depletion reportedly results in EGFR activation (Pike & Casey, 2002; Westover et al., 2003). Although EGFR phosphorylation is associated with oncogenic proliferation, sustained activation of EGFR outside of lipid rafts in fact correlates with increased p38 activation, which is pro-apoptotic. Potential modulations of EGFR activation status by dietary lipids will be discussed in Section 4.

Some studies have examined the activation of downstream targets of EGFR signalling, such as the small GTPase Ras (Rogers et al., 2010), after exposure to fatty acids. Ras associates with lipid rafts via palmitoylation (Calder & Yaqoob, 2007), and is involved in cell survival, growth and proliferation (Downward, 2006). Furthermore, enhanced anti-proliferative effects were seen upon co-treatment with an EGFR inhibitor and DHA (Rogers et al., 2010). Another member of the ErbB family, HER2, is the favoured dimerisation partner of other ErbB proteins for receptor activation (Tzahar et al., 1996; Park, B. W. et al., 2000). Oncogenic HER2 dimerisation in breast cancer cells takes place in lipid rafts (Nagy et al., 2002), and forced exclusion of HER2 from rafts (via crosslinking of the raft-associated ganglioside GM1) has been shown to decrease HER2 dimerisation and tyrosine phosphorylation (Nagy et al., 2002). Another possible avenue of HER2 signalling regulation by lipid rafts relates to protein trafficking. HER2 is rapidly recycled back to the cell membrane if endocytosed (Worthylake et al., 1999), which maintains its overexpression at the cell membrane of breast cancer cells. Modulation of lipid metabolism may control HER2 overexpression by increasing its endocytosis and preventing redistribution back to the cell membrane (Paris et al., 2010). For instance, phospholipase C (PLC) has been shown to co-localise with HER2 in lipid raft domains of HER2-overexpressing breast cancer cell lines, and PLC antagonism enhances HER2 internalisation and delays its recycling to the cell membrane, reducing breast cancer cell proliferation (Paris et al., 2010). This implies that lipid rafts play a key role in transduction of this oncogenic signal.

Another protein known to localise in lipid rafts with HER2, in addition to EGFR, is the estrogen receptor (ER) (Marquez et al., 2006). Estrogen signalling is linked to lipid rafts, where ER co-localises with ErbB receptors to modulate growth events (Marquez et al., 2006). Both these receptors may be activated by membrane-bound ER (Razandi et al., 2003), resulting in MAP kinase-dependent ER phosphorylation (Pietras, 2003). As these receptors are reportedly lipid raft-affiliated, interference of this union with lipid rafts may prove to be useful in targeting endocrine resistance in breast cancer.

Insulin-like growth factor-1 receptor (IGF-1R) is another receptor tyrosine kinase whose activation leads to proliferation and differentiation via MAP kinase and PI3 kinase/Akt pathways (Adams et al., 2000). IGF-1R activity has been linked to lipid raft affiliation, particularly caveolae. Stable expression of caveolin-1 in MCF7 breast cancer cells, while decreasing cell attachment (Fiucci et al., 2002), results in enhanced matrix-independent
cell survival via upregulation of IGF-1R and subsequent activation of p53 and p21 (Ravid et al., 2005). Caveolin-1 further drives IGF-1R-induced recruitment of β1-integrin into lipid rafts (Salani et al., 2009), which could in turn regulate the influence of β1-integrin on cell fate (Li et al., 2005). In fact segregation of IGF-1R in and out of rafts has been shown to dynamically regulate overall signalling potency of the protein (Remacle-Bonnet et al., 2005), which is emerging as a promising pharmaceutical target in breast cancer (Weroha & Haluska, 2008).

Sigma receptors are a novel family of receptors whose physiological and pathophysiological roles are only beginning to emerge. They inhibit proliferation, induce apoptosis and can decrease cell adhesion in mammary carcinoma cell lines (reviewed in Aydar et al., 2004). Sigma receptors were proposed to have the ability to remodel lipid rafts by modulating raft cholesterol levels via cholesterol-binding motifs (Gebreselassie & Bowen, 2004; Takebayashi et al., 2004). Accordingly, raft cholesterol levels are reduced following sigma-1 gene knockdown (Palmer et al., 2007). Sigma-1 receptors also form a complex with β1-integrin in MDA-MB-231 cells, and their translocation outside rafts decreases breast cancer cell growth and adhesion (Palmer et al., 2007). Because cancer cells have elevated levels of lipid rafts and cholesterol (Li et al., 2006), and because many growth signalling molecules depend on rafts to exert their functions, dietary fat modifications could affect signal transduction in breast cancer cells (as will be further addressed in Section 4).

3.3 Cell migration and metastasis

Cancer progression does not depend solely on increased growth and reduced apoptosis, but also on the ability of tumours to seek out new niches to support their continued survival. Accordingly, cells often activate pathways that reduce adhesion and promote cell migration, increasing the likelihood of the metastatic spread of breast cancer.

Kinases play a significant role in regulating cell adhesion and migration. The Src family of kinases (SFK) integrates signal transduction from many receptor tyrosine kinases, including EGFR, IGF-1R and HER2 (Belsches-Jablonski et al., 2001; Parsons & Parsons, 2004) to multiple downstream targets including PI3-kinase, Ras and focal adhesion kinase (Parsons & Parsons, 2004). SFK activation has been linked to lipid rafts in breast cancer cells (Hitosugi et al., 2007), fuelling speculation that selective targeting of raft-affiliated SFK may offer a more potent therapy than conventional SFK inhibitors such as dasatinib. Src has also been shown to phosphorylate the raft marker flotilllin-2 in an EGF-dependent manner, resulting in Src translocation into endosomes and the enhancement of cell spreading (Neumann-Giesen et al., 2007). Conversely, the finding that flotillin-2 knockdown reduces cell spreading further highlights the potential regulatory influence of lipid rafts on cell adhesion and actin dynamics (Neumann-Giesen et al., 2007).

Lipid rafts and caveolin-1 have also been shown to be crucial for the formation of invadopodia, membrane protrusions that penetrate the surrounding matrix through a combination of matrix remodelling and physical force (Buccione et al., 2009). Invadopodia cluster together proteins involved in actin cytoskeleton organisation, signalling, cell-ECM adhesion and membrane remodelling (Gimona et al., 2008). Lipid rafts have been reported to be concentrated at the leading edge of invadopodia in a panel of breast cancer cell lines, and disruption of lipid rafts may suppress invadopodia formation (Yamaguchi et al., 2009). Invasive potential has also been linked with the raft-affiliated proteins caveolin-1 and membrane type 1 matrix metalloproteinase (MMP14) in both breast (Annabi et al., 2001) and
prostate (Wang et al., 2009) cancer cells. In fact caveolin-1 and MMP14 have been shown to co-associate (Labrecque et al., 2004) and to be co-trafficked in invasive breast cancer cell lines (Yamaguchi et al., 2009). Accordingly, a reduction in matrix degradation activity of MMP14 has been reported in MDA-MB-231 cells following disruption of lipid rafts by cholesterol depletion or after knockdown of caveolin-1 in MMP14-overexpression MDA-MB-231 cells (Yamaguchi et al., 2009). Together these results highlight that lipid rafts and caveolin-1 are important for invadopodia function in breast cancer cells.

MMP14 is not the only lipid raft-affiliated proteinase implicated in breast cancer progression. Aberrant expression of MMP2 and MMP9, which localize in rafts during cancer cell migration (Patra, 2008), have been associated with high-grade breast cancer (Mira et al., 2004). Downregulation of MMP2 and MMP9 has been shown to decrease tumour cell invasion (Patra, 2008). Similarly, the serine protease urokinase-type plasminogen activator (uPA) and its receptor (uPAR), which have been linked to breast cancer progression and metastasis (Patra, 2008; Sahores et al., 2008), localise to lipid rafts during cancer cell migration (Sahores et al., 2008). A recent study investigating the importance of lipid rafts in regulating uPAR and MMP9 functionality in breast cancer has demonstrated that cholesterol depletion reduces co-localisation of uPAR and MMP9 with lipid rafts and significantly decreases their total protein and mRNA levels (Raghu et al., 2010). Lipid raft disruption in breast cancer cells resulted in reduced amounts of active Src, FAK, Akt and ERK and increased uPAR co-localisation with lysosomal markers, which was reversed after cholesterol repletion (Raghu et al., 2010). This is in agreement with previous observations of differences in MMP9-driven cell migration according to its sub-cellular localisation inside or outside rafts (Mira et al., 2004).

Although controversial, another approach to understanding breast cancer metastasis comes from the observation that disseminated tumour cells have progenitor-like properties, termed “cancer stem cells” (Acconcia et al., 2004). Low expression of CD24, a ligand for P-selectin on cancer and myeloid cells (Aigner et al., 1997), has been proposed as a marker for cancer stem cells, and breast cancer patients with aggressive triple-negative disease reportedly have higher percentages of cancer stem-like cells (May et al., 2011; Reuben et al., 2011). CD24 appears to govern the localization and function of the chemokine receptor CXCR4, which regulates proliferation in primary and metastatic breast cancer (Smith et al., 2004). CXCR4 must localise in lipid rafts for effective signalling (Manes et al., 2001; Wysoczynski et al., 2005), and CD24 reportedly reduces cellular responsiveness to CXCR4 signalling in a metastatic breast cancer cell line by excluding the latter from lipid rafts (Schabath et al., 2006). Thus low CD24 levels in putative cancer stem cells would have a positive effect on CXCR4-driven proliferative signalling, via enhanced raft affiliation of CXCR4. Accordingly, high expression of CD24 has been shown to reduce tumour growth and spread in mice (Schabath et al., 2006). Therefore CXCR4 metastatic potential may be modulated by altering its affiliation with rafts independently of its expression levels.

Another proposed marker for breast cancer stem cells is CD44 (Blick et al., 2010; May et al., 2011), a multi-functional lipid raft-affiliated transmembrane glycoprotein expressed in a variety of tissues (Murai et al., 2011). CD44 is the major receptor for the extracellular matrix component hyaluronan (HA) (Herrera-Gayol & Jothy, 1999); but it can also act as a co-receptor for growth factors (Bourguignon et al., 1997; Orian-Rousseau et al., 2002) and organise the cellular actin cytoskeleton through cytoplasmic linker proteins (Ponta et al., 2003). CD44 abnormalities have been associated with aggressive histological features of
breast cancer (Joensuu et al., 1993; Diaz et al., 2005), and the association of CD44 with MMP9 in breast tumour cells promotes tumour cell migration and invasion (Bourguignon et al., 1998). It is possible that this matrix-degrading association takes place in lipid rafts, where both CD44 and MMP9 localize. Interactions between CD44 and HA also stimulate a variety of events leading to tumour progression, including Rho kinase activation, Ras signalling and others (reviewed in Bourguignon, 2008). Although the exact mechanisms of these events have yet to be clarified, one proposed method involves CD44 interaction with ankyrin within lipid rafts (Singleton & Bourguignon, 2004). Another matrix glucosaminoglycan, osteopontin, can also activate CD44 to promote cell survival and increased endothelial adhesion by recruiting Src and integrins into lipid rafts (Lee et al., 2008).

The influence of CD44 on cancer progression also extends to other growth factor signalling pathways, since it has previously been demonstrated that the growth factor receptor c-Met cannot be activated by its ligand alone, but also requires CD44 co-expression (van der Voort et al., 1999). c-Met, which has been shown to localise in lipid rafts and whose signalling is sensitive to cholesterol depletion (Coleman et al., 2009), is frequently dysregulated in metastatic breast cancer (Gastaldi et al., 2010; Elnagar et al., 2011). It can thus be hypothesised that lipid rafts are required for successful transduction of growth factor-mediated oncogenic signals through formation of functional CD44 complexes.

Taken altogether, several key molecules frequently implicated in breast cancer initiation, growth and migration are regulated by lipid rafts via sequestration, endocytosis or termination of protein interactions. Considering the ongoing need to develop drugs which selectively attack cancer cells while leaving normal cells unaltered, the imbalance in lipid raft composition between tumour and normal cells may suggest rafts as attractive and novel pharmacological targets in the battle against breast cancer.

4. Lipid rafts as novel therapeutic targets in breast cancer

This section will focus on current cancer treatments targeting lipid rafts, the potential importance of lipid raft modulation to overcome mechanisms of drug resistance, and new mechanisms associated with lipid raft physiology that could be targeted by novel drugs. Finally it will discuss the importance of the diet in influencing lipid raft physiology as a potential mechanism to prevent or reduce cancer dissemination.

4.1 Current drug treatments targeting lipid rafts

There is growing interest in the possibility of targeting lipid rafts for cancer treatments due to their role in the regulation of many steps of tumour transformation and progression, such as the apoptotic pathways initiated by FasL and TRAIL. Current treatments targeting lipid rafts are mainly focused on activating these apoptotic pathways in cancer cells. However many classes of drugs routinely used in breast cancer chemotherapy have been shown to exert some of their effects by modulating lipid rafts.

One key example is cisplatin, whose mechanism of action is still incompletely understood, but which has been described to exert some of its actions through modulation of ceramide lipid rafts. In a human colon cancer cell line, cisplatin induced clustering of the Fas receptor in membrane lipid rafts by activating the acid sphingomyelinase (ASMase), which produces ceramide and is responsible for induction of apoptosis. Nystatin, a compound which disrupts lipid rafts, completely reversed this effect (Lacour et al., 2004). It has also been
reported that a combination of cisplatin and an anti-Fas antibody in cells expressing sphingomyelinase induced marked apoptosis of cancer cells (Huang et al., 2010). Moreover, histone deacetylase inhibitors (HDACi), powerful tumour suppressors for many different solid and hematologic cancers, have also been shown to modulate lipid raft physiology. These compounds act on tumour cells by inducing accumulation of acetylated proteins that can cause growth arrest, apoptosis and ROS-induced cell death (Marks & Xu, 2009). Since normal cells are resistant to these treatments, HDACi have been widely tested in clinical trials alone or in combination with other drugs (Marks & Xu, 2009). Van Oosten and colleagues observed a drastic increase in the expression and localization of TRAIL in lipid rafts after treatment of prostate cancer cells with a HDACi depsipeptide, inducing elevated cell apoptosis (Vanoosten et al., 2005). Similarly, in preclinical mouse breast cancer models the HDACi vorinostat, in combination with administration of monoclonal antibodies against the mouse TRAIL receptor (DR5), induced robust cell apoptosis (Frew et al., 2008). Likewise, some derivatives of doxorubicin, an anthracycline widely used in breast cancer adjuvant chemotherapy, exercise their actions by activating lipid raft-associated pathways. Aroui and colleagues illustrated that treatment of MDA-MB-231 cells with Dox-CPP, obtained by conjugating doxorubicin to a cell-penetrating peptide, sensitised cells to TRAIL-induced apoptotic pathways by increasing TRAIL clustering and its inclusion in ceramide lipid rafts (Aroui et al., 2009). Lipid raft-mediated activation of TRAIL is also important because it reduces resistance mechanisms associated with doxorubicin resistance.

4.2 Overcoming drug resistance by targeting lipid rafts

One major drawback of current cancer treatment regimens is the development of drug resistance. Two main mechanisms have been described to be involved in this multifactorial process: 1) alterations in tumour cell physiology that cause either insensitivity to drug-induced apoptosis or induction of drug-detoxifying mechanisms; 2) expression of energy-dependent transporters that detect and eject anti-cancer drugs from cells (Wang et al., 2010). Recent evidence points to the correlation of both mechanisms with lipid raft physiology. Mechanisms of breast cancer resistance to the anti-HER2 therapeutic antibody Herceptin/Trastuzumab may involve compensatory signalling through dimerisation of HER2 with other ErbB family members, cross-talk between HER2 and the IGF-1R pathway, coverage of the antibody binding site by MUC4 overexpression, and constitutive activation of the PI3 kinase/Akt pathways (Nahta & Esteva, 2006). Interestingly, all these events take place in lipid raft compartments and are involved in the activation of alternative oncogenic pathways to overcome the inhibitory effects of cancer treatments. Therefore, treatments altering lipid raft physiology could provide hope in preventing or reducing mechanisms of resistance to specific anti-cancer drugs.

HER2 over-expression in breast cancer cells has also been reported to stimulate fatty acid synthase (FASyn) gene expression (Menendez et al., 2004). FASyn is a major lipogenic enzyme catalyzing the synthesis of long-chain saturated fatty acids, which localize to lipid rafts in epithelial cells. Accordingly, FASyn inhibitors work by altering lipid raft physiology through deregulation of fatty acid synthesis; and have been reported to re-sensitise cells to Trastuzumab, causing growth inhibition and apoptotic cell death. Since these inhibitors also affect EGFR1 localization to lipid rafts, they may also disrupt the cross-talk between HER2 and EGFR which is involved in Trastuzumab resistance (reviewed in Menendez, 2005). Correspondingly, since ER can localize to lipid rafts through post-translational lipid modifications termed acylations, lipid rafts have been suggested as the possible location of...
interactions between ER and growth factor receptors which occur during resistance to endocrine therapy (Acconcia et al., 2004; Weinberg et al., 2005; Arpino et al., 2008). Mutations of ER acylation sites impair the ability of ER to activate transcription and cell proliferation in response to estradiol stimulation (Pietras et al., 2005). It is appealing to speculate that combinations of hormonal therapies and treatments altering ER localization to lipid rafts could prevent cross-talk between ER and EGFR pathways; and may be a future therapeutic strategy to reduce drug resistance arising in hormonal therapy. Furthermore, it has been shown that poor responsiveness of breast cancer cells to treatment with the EGFR inhibitor gefitinib may be due to increased localization of EGFR in lipid raft domains. Treatment of breast cells with lipid raft-disrupting agents (such as lovastatin) induced cellular sensitivity to gefitinib, and abrogated proliferative pathways initiated by Akt phosphorylation (Irwin et al., 2010).

However, along with single drug resistance in breast cancer therapy, the phenomenon of multidrug resistance has also been described (Ogretmen & Hannun, 2001). This occurs when resistance to one drug is accompanied by resistance to drugs whose structures and mechanisms of action may be completely different. Several studies have observed alterations of lipid raft components in multidrug-resistant cells, such as increased caveolin-1 expression, larger numbers of caveolae (Lavie et al., 1998) and elevated membrane cholesterol content (Gayet et al., 2005). Lavie and colleagues suggested that an increased number of caveolae may be more of a cause than an effect of multidrug resistance. In fact, caveolae, being capable of effluxing cholesterol, may be used by cancer cells to efflux lipophilic drugs. Since caveolar efficiency to efflux cholesterol or any cytotoxic drug is very low, they hypothesized that a higher number of caveolae is therefore necessary to compensate for drug cytotoxic effects and efflux them efficiently (Lavie et al., 1998).

Cellular lipid changes are also often accompanied by increased expression of ABC transporters which can localize to lipid rafts (Klappe et al., 2009). One member of this family, BCRP/ABCG2, which was discovered and cloned in breast cancer cells (Doyle et al., 1998), has been recently described to localize to lipid rafts. Interestingly, disruption of lipid rafts using methyl-β-cyclodextrin has been shown to cause a 40% decrease in BCRP activity (Storch et al., 2007); further highlighting the potential value of pharmacological raft targeting as a mechanism of reducing multi-drug resistance.

Overall these examples demonstrate the importance of lipid rafts in clustering oncogenic signalling molecules that are involved in breast cancer resistance to current conventional treatments. It is also evident that treatments aimed at preventing or disrupting the localisation of oncogenic signalling mediators (such as HER2, ER, IGF-1R or ABC transporters) in lipid rafts may prove therapeutically useful in combination with current treatments in order to prevent the development of resistance.

### 4.3 Novel lipid raft-mediated approaches in breast cancer treatment

Recently, glycomic studies have highlighted an emerging and critical importance of glycans in influencing lipid raft physiology. Therefore potential future cancer treatments may also indirectly target lipid rafts by targeting glycans. For example, in breast cancer cells, gangliosides (such as the ganglioside GM1 or the O-glycosylated protein MUC4) regulate the formation of EGFR growth factor-responsive heterodimer complexes in lipid rafts (Komatsu et al., 2001). Lipid rafts play a fundamental role in providing a microenvironment favouring functional interactions between glycans and HER2 / HER3, which drive tumour
progression (Komatsu et al., 2001; Nagy et al., 2002). Antibodies targeting MUC4 or treatments targeting gangliosides (i.e. ceramide glycosylation inhibitors or ganglioside-targeted vaccines such as NeuGcGM3 and Theratope) may therefore be possible treatments to interfere with ErbB-driven proliferation of breast cancer cells via modulation of lipid raft physiology (Carr et al., 2003; Ibrahim & Murray, 2003; Julien et al., 2009; Mulens et al., 2010). Raft-dependent endocytosis of paclitaxel-conjugated autocrine motility factor is elevated in metastatic breast cancer cells and has been shown to induce tumour regression and promote survival of tumour-bearing mice (Kojic et al., 2008; Kojic et al., 2007). In addition, some new generation treatments have considered the use of nanoparticles to target lipid raft-affiliated proteins involved in tumour progression and invasion. Conjugated nanoparticles present the advantage of selectively targeting cancer cells without affecting the physiology of normal cells. For example, a study in glioma cells using magnetic nanoparticles conjugated to chlorotoxin (which targets MMP2, a protein highly expressed in glioma tumour cells) demonstrated the induction of lipid-raft mediated endocytosis of MMP2 together with Cl⁻ and K⁺ channels (Veiseh et al., 2009), the latter proteins being involved in regulating cell volume during cell invasion. Using this system, a 98% reduction in invasion was observed in nanoparticle-treated cells compared to controls. In the same manner, MMP2 has also been shown to play a role in breast cancer progression and invasion and has been described as a marker for poor prognosis in ER-negative patients (Ma et al., 2009). Therefore, it is conceivable that an approach similar to the one used by Veiseh et al. might be useful as a companion drug strategy for breast cancer chemotherapy.

4.4 Lipid rafts and diet in cancer progression
Cancer cells generally possess higher levels of saturated fatty acids and cholesterol than normal cells (Li et al., 2006). Emerging evidence thus suggests the potential of diet to influence raft composition and the role of rafts in cancer pathophysiology (section 3.2). Several studies have shown that polyunsaturated fatty acids (PUFAs) may have anticarcinogenic properties (Sauer et al., 2007). The mechanism by which PUFAs work is still incompletely understood, but two mechanisms have been proposed. The first suggests that PUFAs affect the palmitoylation status of lipid raft proteins (Webb et al., 2000); while the second model suggests that PUFAs, having a low affinity for cholesterol due to their bulky structure, reduce raft cholesterol levels and cause displacement of raft proteins (Stulnig et al., 2001). In fact, it has been described that in vivo PUFA supplementation affects lipid raft composition by depleting up to 50% of cholesterol and by altering lipid raft/caveolar protein composition. In comparison to chemical disruption of lipid rafts (e.g. with methyl-β-cyclodextrin and nystatin), PUFA treatment is very selective and depletes only membrane cholesterol without affecting other cellular sources of cholesterol (Ma et al., 2004).

It has also been shown that PUFAs such as EPA and DHA inhibit protein palmitoylation of selected T cell lipid raft proteins (such as Fyn) similarly to the chemical compound 2-bromopalmitate (Webb et al., 2000). Interestingly, in MDA-MB-231 breast cancer cells, PUFAs have been shown to decrease cell proliferation and induce apoptotic cell death probably by decreasing Akt/NFkB signal transduction (Schley et al., 2005). Furthermore, PUFA treatment has been shown to increase EPA and DHA concentrations in lipid rafts, with a corresponding decrease of sphingomyelin, cholesterol and diacylglycerol (Schley et al., 2007). In particular, PUFAs reduce sphingomyelin levels by inducing its hydrolysis to ceramide, which (as discussed) activates pro-apoptotic pathways (Schley et al., 2005).
Section 3 discussed how lipid raft disruption negatively modulates EGFR localization and signalling, and, similarly, PUFAs have been shown to exert pro-apoptotic properties by reducing EGFR localization within lipid rafts, thus inducing a sustained activation of EGFR and p38 phosphorylation in breast cancer cells (Schley et al., 2007). In the same way, (−)-epigallocatechin-3-gallate (EGCG), the active compound contained in green tea, can alter lipid raft domain composition. EGCG has been described to prevent EGF interactions with its receptor, to prevent EGFR dimerisation and to inhibit its localisation within rafts. This would promote pro-apoptotic signalling via p38. Altogether, EGFR translocation alters its activation status and may have anti-cancer effects (Patra et al., 2008). EGCG also exerts further anti-cancer activity by suppressing proliferation and enhancing apoptosis by interfering with lipid raft remodelling (Patra et al., 2008). Indeed, EGCG has been described to block the laminin-1 receptor, a raft-affiliated protein (Tachibana et al., 2004) whose activation is connected with a kinase/phosphatase cascade involved in tumour progression (Patra et al., 2008). Interestingly, EGCG also seems to play a role in modulating multidrug resistance. In fact it has been described that EGCG causes a dose-dependent increase in apoptosis in Trastuzumab- (Eddy et al., 2007), Tamoxifen- and multidrug-resistant breast cancer cells (Farabegoli et al., 2010).

Taken together, we have summarized putative anti-tumour mechanisms involving interference with lipid rafts, and highlighted the importance of rafts as targets for cancer therapy. Development of drugs directed to specific raft components could facilitate widespread use of these treatments; while dietary modification alone could influence tumorigenic behaviour through modulation of lipid raft composition. Overall we suggest that lipid rafts play a key role both in the prevention and treatment of breast cancer, and are confident that further studies in this area will prove highly fruitful in the future.

5. References

Acconcia, F, Ascenzi, P, Fabozzi, G, Visca, P & Marino, M (2004). S-palmitoylation modulates human estrogen receptor-alpha functions. *Biochem Biophys Res Commun, Vol. 316, No. 3, (2004), pp 878-83*

Adams, TE, Epa, VC, Garrett, TP & Ward, CW (2000). Structure and function of the type 1 insulin-like growth factor receptor. *Cell Mol Life Sci, Vol. 57, No. 7, (2000), pp 1050-93*

Aigner, S, Sthoeger, ZM, Fogel, M, Weber, E, Zarn, J et al. (1997). CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. *Blood, Vol. 89, No. 9, (1997), pp 3385-95*

Annabi, B, Lachambre, M, Bousquet-Gagnon, N, Page, M, Gingras, D et al. (2001). Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. *Biochem J, Vol. 353, No. Pt 3, (2001), pp 547-53*

Aroui, S, Brahim, S, Hamelin, J, De Waard, M, Breard, J et al. (2009). Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. *Apoptosis, Vol. 14, No. 11, (2009), pp 1352-65*

Arpino, G, Wiechmann, L, Osborne, CK & Schiff, R (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev, Vol. 29, No. 2, (2008), pp 217-33*
Aydar, E, Palmer, CP & Djamgoz, MB (2004). Sigma receptors and cancer: possible involvement of ion channels. Cancer Res, Vol. 64, No. 15, (2004), pp 5029-35

Babuke, T & Tikkanen, R (2007). Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol, Vol. 86, No. 9, (2007), pp 525-32

Barros, FF, Powe, DG, Ellis, IO & Green, AR (2010). Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology, Vol. 56, No. 5, (2010), pp 560-72

Belsches-Jablonski, AP, Biscardi, JS, Peavy, DR, Tice, DA, Romney, DA et al. (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene, Vol. 20, No. 12, (2001), pp 1465-75

Bhatnagar, RS & Gordon, JI (1997). Understanding covalent modifications of proteins by lipids: where cell biology and biophysics mingle. Trends Cell Biol, Vol. 7, No. 1, (1997), pp 14-20

Bickel, PE, Scherer, PE, Schnitzer, JE, Oh, P, Lisanti, MP et al. (1997). Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem, Vol. 272, No. 21, (1997), pp 13793-802

Bijlmakers, MJ & Marsh, M (2003). The on-off story of protein palmitoylation. Trends Cell Biol, Vol. 13, No. 1, (2003), pp 32-42

Blick, T, Hugo, H, Widodo, E, Waltham, M, Pinto, C et al. (2010). Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi)/CD24(lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia, Vol. 15, No. 2, (2010), pp 235-52

Bourguignon, LY (2008). Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol, Vol. 18, No. 4, (2008), pp 251-9

Bourguignon, LY, Zhu, D & Zhu, H (1998). CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci, Vol. 3, No. (1998), pp d637-49

Bourguignon, LY, Zhu, H, Chu, A, Iida, N, Zhang, L et al. (1997). Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem, Vol. 272, No. 44, (1997), pp 27913-8

Brown, DA & Rose, JK (1992). Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell, Vol. 68, No. 3, (1992), pp 533-44

Buccione, R, Caldieri, G & Ayala, I (2009). Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev, Vol. 28, No. 1-2, (2009), pp 137-49

Calder, PC & Yaqoob, P (2007). Lipid rafts–composition, characterization, and controversies. J Nutr, Vol. 137, No. 3, (2007), pp 545-7

Camp, LA & Hofmann, SL (1995). Assay and isolation of palmitoyl-protein thioesterase from bovine brain using palmitoylated H-Ras as substrate. Methods Enzymol, Vol. 250, No. (1995), pp 336-47

Carr, A, Rodriguez, E, Arango Mdel, C, Camacho, R, Osorio, M et al. (2003). Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol, Vol. 21, No. 6, (2003), pp 1015-21
Lipid Rafts as Master Regulators of Breast Cancer Cell Function

Cary, LA & Cooper, JA (2000). Molecular switches in lipid rafts. *Nature*, Vol. 404, No. 6781, (2000), pp 945, 947

Casey, PJ & Seabra, MC (1996). Protein prenyltransferases. *J Biol Chem*, Vol. 271, No. 10, (1996), pp 5289-92

Chakrabandhu, K, Herincs, Z, Huault, S, Dost, B, Peng, L et al. (2007). Palmitoylation is required for efficient Fas cell death signaling. *EMBO J*, Vol. 26, No. 1, (2007), pp 209-20

Chen, X & Resh, MD (2002). Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. *J Biol Chem*, Vol. 277, No. 51, (2002), pp 49631-7

Colas, S, Maheo, K, Denis, F, Goupille, C, Hoinard, C et al. (2006). Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. *Clin Cancer Res*, Vol. 12, No. 19, (2006), pp 5879-86

Coleman, DT, Bigelow, R & Cardelli, JA (2009). Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. *Mol Cancer Ther*, Vol. 8, No. 1, (2009), pp 214-24

Datta, SR, Brunet, A & Greenberg, ME (1999). Cellular survival: a play in three Akts. *Genes Dev*, Vol. 13, No. 22, (1999), pp 2905-27

de Laurentiis, A, Donovan, L & Arcaro, A (2007). Lipid rafts and caveolae in signaling by growth factor receptors. *Open Biochem J*, Vol. 1, No. (2007), pp 12-32

Deborde, S, Perret, E, Gravotta, D, Deora, A, Salvarezza, S et al. (2008). Clathrin is a key regulator of basolateral polarity. *Nature*, Vol. 452, No. 7188, (2008), pp 719-23

Diaz, LK, Zhou, X, Wright, ET, Cristofanilli, M, Smith, T et al. (2005). CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. *Clin Cancer Res*, Vol. 11, No. 9, (2005), pp 3309-14

Downward, J (2006). Signal transduction. Prelude to an anniversary for the RAS oncogene. *Science*, Vol. 314, No. 5798, (2006), pp 433-4

Doyle, LA, Yang, W, Abruzzo, LV, Krogmann, T, Gao, Y et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A*, Vol. 95, No. 26, (1998), pp 15665-70

Dumitru, CA, Carpinteiro, A, Trarbach, T, Hengge, UR & Gulbins, E (2007). Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. *Apoptosis*, Vol. 12, No. 8, (2007), pp 1533-41

Dunphy, JT, Greenstreet, WK & Linder, ME (2001). Enrichment of G-protein palmitoyltransferase activity in low density membranes: in vitro reconstitution of Galphai to these domains requires palmitoyltransferase activity. *J Biol Chem*, Vol. 276, No. 46, (2001), pp 43300-4

Eddy, SF, Kane, SE & Sonenshein, GE (2007). Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. *Cancer Res*, Vol. 67, No. 19, (2007), pp 9018-23

Elhyany, S, Assa-Kunik, E, Tsory, S, Muller, T, Fedida, S et al. (2004). The integrity of cholesterol-enriched microdomains is essential for the constitutive high activity of protein kinase B in tumour cells. *Biochem Soc Trans*, Vol. 32, No. Pt 5, (2004), pp 837-9
Elnagar, AY, Sylvester, PW & El Sayed, KA (2011). (-)-Oleocanthal as a c-Met Inhibitor for the Control of Metastatic Breast and Prostate Cancers. Planta Med, Vol. No. (2011), 1439-0221

Everson, WV & Smart, EJ. (2006). Caveolin and its Role in Intracellular Chaperone Complexes (edition), Wiley-VCH Verlag GmbH & Co. KGaA, 9783527608072,

Fan, JY, Carpentier, JL, van Obberghen, E, Grunfeld, C, Gorden, P et al. (1983). Morphological changes of the 3T3-L1 fibroblast plasma membrane upon differentiation to the adipocyte form. J Cell Sci, Vol 61, No. (1983), pp 219-30

Farabegoli, F, Papi, A, Bartolini, G, Ostan, R & Orlandi, M (2010). (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine, Vol. 17, No. 5, (2010), pp 356-62

Fiedler, K, Kobayashi, T, Kurzchalia, TV & Simons, K (1993). Glycosphingolipid-enriched, detergent-insoluble complexes in protein sorting in epithelial cells. Biochemistry, Vol. 32, No. 25, (1993), pp 6365-73

Fiucci, G, Ravid, D, Reich, R & Liscovitch, M (2002). Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, Vol. 21, No. 15, (2002), pp 2365-75

Folsch, H, Mattilia, PE & Weisz, OA (2009). Taking the scenic route: biosynthetic traffic to the plasma membrane in polarized epithelial cells. Traffic, Vol. 10, No. 8, (2009), pp 972-81

Fra, AM, Williamson, E, Simons, K & Parton, RG (1995). De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci U S A, Vol. 92, No. 19, (1995), pp 8655-9

Freeman, MR, Cinar, B, Kim, J, Mukhopadhyay, NK, Di Vizio, D et al. (2007). Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids, Vol. 72, No. 2, (2007), pp 210-7

Frew, AJ, Lindemann, RK, Martin, BP, Clarke, CJ, Sharkey, J et al. (2008). Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A, Vol. 105, No. 32, (2008), pp 11317-22

Furuchi, T & Anderson, RG (1998). Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem, Vol. 273, No. 33, (1998), pp 21099-104

Gajate, C, Del Canto-Janex, E, Acuna, AU, Amat-Guerri, F, Geijo, E et al. (2004). Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med, Vol. 200, No. 3, (2004), pp 353-65

Gajate, C, Gonzalez-Camacho, F & Mollinedo, F (2009). Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun, Vol. 380, No. 4, (2009), pp 780-4

Gajate, C & Mollinedo, F (2001). The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, Vol. 98, No. 13, (2001), pp 3860-3

Gajate, C & Mollinedo, F (2005). Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem, Vol. 280, No. 12, (2005), pp 11641-7
Lipid Rafts as Master Regulators of Breast Cancer Cell Function

Gajate, C & Mollinedo, F (2007). Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. *Blood*, Vol. 109, No. 2, (2007), pp 711-9

Galbiati, F, Engelman, JA, Volonte, D, Zhang, XL, Minetti, C et al. (2001). Caveolin-3 null mice show a loss of caveoleae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. *J Biol Chem*, Vol. 276, No. 24, (2001), pp 21425-33

Gastaldi, S, Comoglio, PM & Trusolino, L (2010). The Met oncogene and basal-like breast cancer: another culprit to watch out for? *Breast Cancer Res*, Vol. 12, No. 4, (2010), pp 208

Gayet, L, Dayan, G, Barakat, S, Labialle, S, Michaud, M et al. (2005). Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. *Biochemistry*, Vol. 44, No. 11, (2005), pp 4499-509

Gebreselassie, D & Bowen, WD (2004). Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. *Eur J Pharmacol*, Vol. 493, No. 1-3, (2004), pp 19-28

Germain, E, Chajes, V, Cognault, S, Lhuillery, C & Bougnoux, P (1998). Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. *Int J Cancer*, Vol. 75, No. 4, (1998), pp 578-83

Ghosh, RN, Mallet, WG, Soe, TT, McGraw, TE & Maxfield, FR (1998). An endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking through the endocytic recycling compartment in CHO cells. *J Cell Biol*, Vol. 142, No. 4, (1998), pp 923-36

Gimona, M, Buccione, R, Courtneidge, SA & Linder, S (2008). Assembly and biological role of podosomes and invadopodia. *Curr Opin Cell Biol*, Vol. 20, No. 2, (2008), pp 235-41

Gong, M, Wilson, M, Kelly, T, Su, W, Dressman, J et al. (2003). HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. *J Clin Invest*, Vol. 111, No. 10, (2003), pp 1579-87

Gorelick, FS & Shugrue, C (2001). Exiting the endoplasmic reticulum. *Mol Cell Endocrinol*, Vol. 177, No. 1-2, (2001), pp 13-8

Herrera-Gayol, A & Jothy, S (1999). Adhesion proteins in the biology of breast cancer: contribution of CD44. *Exp Mol Pathol*, Vol. 66, No. 2, (1999), pp 149-56

Hill, MM, Feng, J & Hemmings, BA (2002). Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. *Curr Biol*, Vol. 12, No. 14, (2002), pp 1251-5

Hitosugi, T, Sato, M, Sasaki, K & Umezawa, Y (2007). Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells. *Cancer Res*, Vol. 67, No. 17, (2007), pp 8139-48

Huang, CR, Jin, ZX, Dong, L, Tong, XP, Yue, S et al. (2010). Cisplatin augments FAS-mediated apoptosis through lipid rafts. *Anticancer Res*, Vol. 30, No. 6, (2010), pp 2065-71

Ibrahim, NK & Murray, JL (2003). Clinical development of the STn-KLH vaccine (Theratope). *Clin Breast Cancer*, Vol. 3 Suppl 4, No. (2003), pp S139-43
Irwin, ME, Mueller, KL, Bohin, N, Ge, Y & Boerner, JL (2010). Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. *J Cell Physiol*, Vol. No. (2010), 1097-4652

Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E et al. (2011). Global cancer statistics. *CA Cancer J Clin*, Vol. 61, No. 2, (2011), pp 69-90

Joensuu, H, Klemi, PJ, Toikkanen, S & Jalkanen, S (1993). Glycoprotein CD44 expression and its association with survival in breast cancer. *Am J Pathol*, Vol. 143, No. 3, (1993), pp 867-74

Julien, S, Picco, G, Sewell, R, Vercoutter-Edouart, AS, Tarp, M et al. (2009). Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. *Br J Cancer*, Vol. 100, No. 11, (2009), pp 1746-54

Kang, R, Wan, J, Arstikaitis, P, Takahashi, H, Huang, K et al. (2008). Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. *Nature*, Vol. 456, No. 7224, (2008), pp 904-9

Klappe, K, Hummel, I, Hoekstra, D & Kok, JW (2009). Lipid dependence of ABC transporter localization and function. *Chem Phys Lipids*, Vol. 161, No. 2, (2009), pp 57-64

Komatsu, M, Jepson, S, Arango, ME, Carothers Carraway, CA & Carraway, KL (2001). Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. *Oncogene*, Vol. 20, No. 4, (2001), pp 461-70

Labrecque, M, Nyalendo, C, Langlois, S, Durocher, Y, Roghi, C et al. (2004). Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. *J Biol Chem*, Vol. 279, No. 50, (2004), pp 52132-40

Lacour, S, Hammann, A, Grazide, S, Lagadic-Gossmann, D, Athias, A et al. (2004). Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. *Cancer Res*, Vol. 64, No. 10, (2004), pp 3593-8

Lajoie, P & Nabi, IR (2010). Lipid rafts, caveolae, and their endocytosis. *Int Rev Cell Mol Biol*, Vol. 282, No. (2010), pp 135-63

Lajoie, P, Partridge, EA, Guay, G, S., N, Goetz, JG et al. (2007). Plasma membrane domain organization regulates EGFR signaling in tumor cells. *J Cell Biol*, Vol. 179, No. 2, (2007), pp 341-56

Landowski, TH, Gleason-Guzman, MC & Dalton, WS (1997). Selection for drug resistance results in resistance to Fas-mediated apoptosis. *Blood*, Vol. 89, No. 6, (1997), pp 1854-61

Lavie, Y, Fiucci, G & Liscovitch, M (1998). Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. *J Biol Chem*, Vol. 273, No. 49, (1998), pp 32380-3

Le Moyec, L, Tatoud, R, Eugene, M, Gauville, C, Primot, I et al. (1992). Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines. *Br J Cancer*, Vol. 66, No. 4, (1992), pp 623-8

Lee, JL, Wang, MJ, Sudhir, PR & Chen, JY (2008). CD44 engagement promotes matrix-derived survival through the CD44-SRC-integrin axis in lipid rafts. *Mol Cell Biol*, Vol. 28, No. 18, (2008), pp 5710-23

Lee, SH, Koo, KH, Park, JW, Kim, HJ, Ye, SK et al. (2009). HIF-1 is induced via EGFR activation and mediates resistance to anoikis-like cell death under lipid...
rafts/caveolae-disrupting stress. *Carcinogenesis*, Vol. 30, No. 12, (2009), pp 1997-2004

Leon, L, Subramaniam, S, Cauvard, O, Plenchette-Colas, S, Paul, C et al. (2011). S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand-Mediated Apoptosis in Cancer Cells. *Gastroenterology*, Vol. No. (2011), 1528-0012

Levental, I, Grzybek, M & Simons, K (2010). Greasing their way: lipid modifications determine protein association with membrane rafts. *Biochemistry*, Vol. 49, No. 30, (2010), pp 6305-16

Li, H, Zhu, H, Xu, CJ & Yuan, J (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell*, Vol. 94, No. 4, (1998), pp 491-501

Li, N, Zhang, Y, Naylor, MJ, Schatzmann, F, Maurer, F et al. (2005). Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. *EMBO J*, Vol. 24, No. 11, (2005), pp 1942-53

Li, YC, Park, MJ, Ye, SK, Kim, CW & Kim, YN (2006). Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. *Am J Pathol*, Vol. 168, No. 4, (2006), pp 1107-18

Lingwood, D, Kaiser, HJ, Levental, I & Simons, K (2009). Lipid rafts as functional heterogeneity in cell membranes. *Biochem Soc Trans*, Vol. 37, No. Pt 5, (2009), pp 955-60

Lipowsky, R (1993). Domain-induced budding of fluid membranes. *Biophys J*, Vol. 64, No. 4, (1993), pp 1133-8

Liu, J, Deyoung, SM, Zhang, M, Dold, LH & Saltiel, AR (2005). The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. *J Biol Chem*, Vol. 280, No. 16, (2005), pp 16125-34

Lobo, S, Greentree, WK, Linder, ME & Deschenes, RJ (2002). Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae. *J Biol Chem*, Vol. 277, No. 43, (2002), pp 41268-73

Ma, DW, See, J, Switzer, KC, Fan, YY, McMurray, DN et al. (2004). n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. *J Nutr Biochem*, Vol. 15, No. 11, (2004), pp 700-6

Ma, XJ, Dahiya, S, Richardson, E, Erlander, M & Sgroi, DC (2009). Gene expression profiling of the tumor microenvironment during breast cancer progression. *Breast Cancer Res*, Vol. 11, No. 1, (2009), pp R7, 1465-542X

Magee, Al & Seabra, MC (2003). Are prenyl groups on proteins sticky fingers or greasy handles? *Biochem J*, Vol. 376, No. Pt 2, (2003), pp e3-4

Manes, S, Lacalle, RA, Gomez-Mouton, C, del Real, G, Mira, E et al. (2001). Membrane raft microdomains in chemokine receptor function. *Semin Immunol*, Vol. 13, No. 2, (2001), pp 147-57

Marks, PA & Xu, WS (2009). Histone deacetylase inhibitors: Potential in cancer therapy. *J Cell Biochem*, Vol. 107, No. 4, (2009), pp 600-8

Marquez, DC, Chen, HW, Curran, EM, Welshons, WV & Pietras, RJ (2006). Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. *Mol Cell Endocrinol*, Vol. 246, No. 1-2, (2006), pp 91-100
May, CD, Sphyris, N, Evans, KW, Werden, SJ, Guo, W et al. (2011). Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res, Vol. 13, No. 1, (2011), pp 202

McGuire, TF, Corey, SJ & Sebti, SM (1993). Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor. J Biol Chem, Vol. 268, No. 30, (1993), pp 22227-30

Mellman, I & Nelson, WJ (2008). Coordinated protein sorting, targeting and distribution in polarized cells. Nat Rev Mol Cell Biol, Vol. 9, No. 11, (2008), pp 833-45

Menendez, JA, Lupu, R & Colomer, R (2005). Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev, Vol. 14, No. 3, (2005), pp 263-70

Menendez, JA, Vellon, L, Mehmi, I, Oza, BP, Ropero, S et al. (2004). Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A, Vol. 101, No. 29, (2004), pp 10715-20

Merino, D, Lalaoui, N, Morizot, A, Schneider, P, Solary, E et al. (2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol, Vol. 26, No. 19, (2006), pp 7046-55

Mineo, C, Gill, GN & Anderson, RG (1999). Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem, Vol. 274, No. 43, (1999), pp 30363-43

Mira, E, Lacalle, RA, Buesa, JM, de Buitrago, GG, Jimenez-Baranda, S et al. (2004). Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci, Vol. 117, No. Pt 9, (2004), pp 1847-57

Morrow, IC, Rea, S, Martin, S, Prior, IA, Prohaska, R et al. (2002). Flotillin-1/reggie-2 traffics to surface raft domains via a novel golgi-independent pathway. Identification of a novel membrane targeting domain and a role for palmitoylation. J Biol Chem, Vol. 277, No. 50, (2002), pp 48834-41

Mulens, V, de la Torre, A, Marinello, P, Rodriguez, R, Cardoso, J et al. (2010). Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin, Vol. 6, No. 9, (2010), 1554-8619

Murai, T, Maruyama, Y, Mio, K, Nishiyama, H, Suga, M et al. (2011). Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration. J Biol Chem, Vol. 286, No. 3, (2011), pp 1999-2007

Murata, M, Peranen, J, Schreiner, R, Wieland, F, Kurzchalia, TV et al. (1995). VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A, Vol. 92, No. 22, (1995), pp 10339-43

Nabi, IR & Le, PU (2003). Caveolae/raft-dependent endocytosis. J Cell Biol, Vol. 161, No. 4, (2003), pp 673-7

Nagy, P, Vereb, G, Sebestyen, Z, Horvath, G, Lockett, SJ et al. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci, Vol. 115, No. Pt 22, (2002), pp 4251-62

Nahta, R & Esteva, FJ (2006). HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res, Vol. 8, No. 6, (2006), pp 215, 1465-542X
Neumann-Giesen, C, Falkenbach, B, Beicht, P, Claasen, S, Luers, G et al. (2004). Membrane and raft association of reggie-1/flotillin-2: role of myristoylation, palmitoylation and oligomerization and induction of filopodia by overexpression. *Biochem J*, Vol. 378, No. Pt 2, (2004), pp 509-18

Neumann-Giesen, C, Fernow, I, Amaddii, M & Tikkanen, R (2007). Role of EGF-induced tyrosine phosphorylation of reggie-1/flotillin-2 in cell spreading and signaling to the actin cytoskeleton. *J Cell Sci*, Vol. 120, No. Pt 3, (2007), pp 395-406

Nohara, K, Wang, F & Spiegel, S (1998). Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. *Breast Cancer Res Treat*, Vol. 48, No. 2, (1998), pp 149-57

Ogretmen, B & Hannun, YA (2001). Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. *Drug Resist Updat*, Vol. 4, No. 6, (2001), pp 368-77

Okamoto, T, Schlegel, A, Scherer, PE & Lisanti, MP (1998). Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. *J Biol Chem*, Vol. 273, No. 10, (1998), pp 5419-22

Orian-Rousseau, V, Chen, L, Sleeman, JP, Herrlich, P & Ponta, H (2002). CD44 is required for two consecutive steps in HGF/c-Met signaling. *Genes Dev*, Vol. 16, No. 23, (2002), pp 3074-86

Paladino, S, Lebreton, S, Tivodar, S, Campana, V, Tempre, R et al. (2008). Different GPI-attachment signals affect the oligomerisation of GPI-anchored proteins and their apical sorting. *J Cell Sci*, Vol. 121, No. Pt 24, (2008), pp 4001-7

Paladino, S, Sarnataro, D, Pillich, R, Tivodar, S, Nitsch, L et al. (2004). Protein oligomerization modulates raft partitioning and apical sorting of GPI-anchored proteins. *J Cell Biol*, Vol. 167, No. 4, (2004), pp 699-709

Palmer, CP, Mahen, R, Schnell, E, Djamgoz, MB & Aydar, E (2007). Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. *Cancer Res*, Vol. 67, No. 23, (2007), pp 11166-75

Paris, L, Cecchetti, S, Spadaro, F, Abalsamo, L, Lugini, L et al. (2010). Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. *Breast Cancer Res*, Vol. 12, No. 3, (2010), pp R27, 1465-542X

Park, BW, Zhang, HT, Wu, C, Berezov, A, Zhang, X et al. (2000). Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. *Nat Biotechnol*, Vol. 18, No. 2, (2000), pp 194-8

Park, EK, Lee, EJ, Lee, SH, Koo, KH, Sung, JY et al. (2010). Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. *Br J Pharmacol*, Vol. 160, No. 5, (2010), pp 1212-23

Park, EK, Park, MJ, Lee, SH, Li, YC, Kim, J J et al. (2009). Cholesterol depletion induces anoikis-like apoptosis via FAK down-regulation and caveolae internalization. *J Pathol*, Vol. 218, No. 3, (2009), pp 337-49

Parmryd, I, Adler, J, Patel, R & Magee, AI (2003). Imaging metabolism of phosphatidylinositol 4,5-bisphosphate in T-cell GM1-enriched domains containing Ras proteins. *Exp Cell Res*, Vol. 285, No. 1, (2003), pp 27-38

Parpal, S, Karlsson, M, Thorn, H & Stralfors, P (2001). Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor
substrate-1, but not for mitogen-activated protein kinase control. *J Biol Chem*, Vol. 276, No. 13, (2001), pp 9670-8

Parsons, SJ & Parsons, JT (2004). Src family kinases, key regulators of signal transduction. *Oncogene*, Vol. 23, No. 48, (2004), pp 7906-9

Patra, SK (2008). Dissecting lipid raft facilitated cell signaling pathways in cancer. *Biochim Biophys Acta*, Vol. 1785, No. 2, (2008), pp 182-206

Patra, SK, Rizzi, F, Silva, A, Rugina, DO & Bettuzzi, S (2008). Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. *J Physiol Pharmacol*, Vol. 59 Suppl 9, No. (2008), pp 217-35

Peter, ME & Krammer, PH (2003). The CD95(APO-1/Fas) DISC and beyond. *Cell Death Differ*, Vol. 10, No. 1, (2003), pp 26-35

Pietras, RJ (2003). Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. *Breast J*, Vol. 9, No. 5, (2003), pp 361-73

Pietras, RJ, Marquez, DC, Chen, HW, Tsai, E, Weinberg, O et al. (2005). Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. *Steroids*, Vol. 70, No. 5-7, (2005), pp 372-81

Pike, LJ (2003). Lipid rafts: bringing order to chaos. *J Lipid Res*, Vol. 44, No. 4, (2003), pp 655-67

Pike, LJ & Casey, L (2002). Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. *Biochemistry*, Vol. 41, No. 32, (2002), pp 10315-22

Planey, SL & Zacharias, DA (2009). Palmitoyl acyltransferases, their substrates, and novel assays to connect them (Review). *Mol Membr Biol*, Vol. 26, No. 1, (2009), pp 14-31

Ponta, H, Sherman, L & Herrlich, PA (2003). CD44: from adhesion molecules to signalling regulators. *Nat Rev Mol Cell Biol*, Vol. 4, No. 1, (2003), pp 33-45

Prinetti, A, Chigorno, V, Tettamanti, G & Sonnino, S (2000). Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. *J Biol Chem*, Vol. 275, No. 16, (2000), pp 11658-65

Prior, IA & Hancock, JF (2001). Compartmentalization of Ras proteins. *J Cell Sci*, Vol. 114, No. Pt 9, (2001), pp 1603-8

Raghu, H, Sodadasu, PK, Malla, RR, Gondi, CS, Estes, N et al. (2010). Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. *BMC Cancer*, Vol. 10, No. (2010), pp 647, 1471-2407

Ravid, D, Maor, S, Werner, H & Liscovitch, M (2005). Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. *Oncogene*, Vol. 24, No. 8, (2005), pp 1338-47

Razandi, M, Pedram, A, Park, ST & Levin, ER (2003). Proximal events in signaling by plasma membrane estrogen receptors. *J Biol Chem*, Vol. 278, No. 4, (2003), pp 2701-12

Reimer, T, Herrnring, C, Koczan, D, Richter, D, Gerber, B et al. (2000). FasL:Fas ratio—a prognostic factor in breast carcinomas. *Cancer Res*, Vol. 60, No. 4, (2000), pp 822-8

Remacle-Bonnet, M, Garrouste, F, Baillat, G, Andre, F, Marvaldi, J et al. (2005). Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. *Am J Pathol*, Vol. 167, No. 3, (2005), pp 761-73
Lipid Rafts as Master Regulators of Breast Cancer Cell Function

Reuben, JM, Lee, BN, Gao, H, Cohen, EN, Mego, M et al. (2011). Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)/CD24(lo) cancer stem cell phenotype. Eur J Cancer, Vol. No. (2011), 1879-0852

Ringerike, T, Blystad, FD, Levy, FO, Madshus, IH & Stang, E (2002). Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci, Vol. 115, No. Pt 6, (2002), pp 1331-40

Rodriguez-Boulan, E, Kreitzer, G & Musch, A (2005). Organization of vesicular trafficking in epithelia. Nat Rev Mol Cell Biol, Vol. No. 3, (2005), pp 233-47

Rogers, KR, Kikawa, KD, Mouradian, M, Hernandez, K, McKinnon, KM et al. (2010). Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis, Vol. 31, No. 9, (2010), pp 1523-30

Rossin, A, Derouet, M, Abdel-Sater, F & Hueber, AO (2009). Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J, Vol. 419, No. 1, (2009), pp 185-92

Roth, AF, Feng, Y, Chen, L & Davis, NG (2002). The yeast DHHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase. J Cell Biol, Vol. 159, No. 1, (2002), pp 23-8

Rothberg, JM & Artavanis-Tsakonas, S (1992). Modularity of the slit protein. Characterization of a conserved carboxy-terminal sequence in secreted proteins and a motif implicated in extracellular protein interactions. J Mol Biol, Vol. 227, No. 2, (1992), pp 367-70

Rothberg, KG, Heuser, JE, Donzell, WC, Ying, Y-S, Glenney, JR et al. (1992). Caveolin, a protein component of caveolae membrane coats. Cell, Vol. 68, No. (1992), pp 673-682

Rothberg, KG, Ying, YS, Kolhouse, JF, Kamen, BA & Anderson, RG (1990). The glycoprophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J Cell Biol, Vol. 110, No. 3, (1990), pp 637-49

Rubin, J, Schwartz, Z, Boyan, BD, Fan, X, Case, N et al. (2007). Caveolin-1 knockout mice have increased bone size and stiffness. J Bone Miner Res, Vol. 22, No. 9, (2007), pp 1408-18

Sahores, M, Prinetti, A, Chiabrando, G, Blasi, F & Sonnino, S (2008). uPA binding increases UPAR localization to lipid rafts and modifies the receptor microdomain composition. Biochim Biophys Acta, Vol. 1778, No. 1, (2008), pp 250-9

Salani, B, Briatore, L, Contini, P, Passalacqua, M, Melloni, E et al. (2009). IGF-I induced rapid recruitment of integrin beta1 to lipid rafts is Caveolin-1 dependent. Biochem Biophys Res Commun, Vol. 380, No. 3, (2009), pp 489-92

Sauer, LA, Blask, DE & Dauchy, RT (2007). Dietary factors and growth and metabolism in experimental tumors. J Nutr Biochem, Vol. 18, No. 10, (2007), pp 637-49

Schabath, H, Runz, S, Joumaa, S & Altevogt, P (2006). CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci, Vol. 119, No. Pt 2, (2006), pp 314-25

Schley, PD, Brindley, DN & Field, CJ (2007). (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr, Vol. 137, No. 3, (2007), pp 548-53
Schley, PD, Jijon, HB, Robinson, LE & Field, CJ (2005). Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat, Vol. 92, No. 2, (2005), pp 187-95

Schuck, S & Simons, K (2004). Polarized sorting in epithelial cells: raft clustering and the biogenesis of the apical membrane. J Cell Sci, Vol. 117, No. Pt 25, (2004), pp 5955-64

Simons, K & Ikonen, E (1997). Functional rafts in cell membranes. Nature, Vol. 387, No. 6633, (1997), pp 569-72

Simons, K & Toomre, D (2000). Lipid rafts and signal transduction. Nat Rev Mol Cell Biol, Vol. 1, No. 1, (2000), pp 31-9

Singleton, PA & Bourguignon, LY (2004). CD44 interaction with ankyrin and IP3 receptor in lipid rafts promotes hyaluronan-mediated Ca^{2+} signaling leading to nitric oxide production and endothelial cell adhesion and proliferation. Exp Cell Res, Vol. 295, No. 1, (2004), pp 102-18

Smith, MC, Luker, KE, Garbow, JR, Prior, JL, Jackson, E et al. (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res, Vol. 64, No. 23, (2004), pp 8604-12

Song, J, Sapi, E, Brown, W, Nilsen, J, Tartaro, K et al. (2000). Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest, Vol. 106, No. 10, (2000), pp 1209-20

Song, JH, Tse, MC, Bellail, A, Phuphanich, S, Khuri, F et al. (2007). Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res, Vol. 67, No. 14, (2007), pp 6946-55

Storch, CH, Ehehalt, R, Haefeli, WE & Weiss, J (2007). Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther, Vol. 323, No. 1, (2007), pp 257-64

Stuermer, CA, Langhorst, MF, Wiechers, MF, Legler, DF, Von Hanwehr, SH et al. (2004). PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J, Vol. 18, No. 14, (2004), pp 1731-3

Stulnig, TM, Huber, J, Leitinger, N, Imre, EM, Angelisova, P et al. (2001). Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J Biol Chem, Vol. 276, No. 40, (2001), pp 37335-40

Tachibana, H, Koga, K, Fujimura, Y & Yamada, K (2004). A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol, Vol. 11, No. 4, (2004), pp 380-1

Takebayashi, M, Hayashi, T & Su, TP (2004). Sigma-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: potential relation to lipid raft reconstitution. Synapse, Vol. 53, No. 2, (2004), pp 90-103

Tang, Z, Scherer, PE, Okamoto, T, Song, K, Chu, C et al. (1996). Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem, Vol. 271, No. 4, (1996), pp 2255-61

Tavernarakis, N, Driscoll, M & Kyrpies, NC (1999). The SPFH domain: implicated in regulating targeted protein turnover in stomatins and other membrane-associated proteins. Trends Biochem Sci, Vol. 24, No. 11, (1999), pp 425-7
Lipid Rafts as Master Regulators of Breast Cancer Cell Function

Tran, D, Carpentier, JL, Sawano, F, Gorden, P & Orci, L (1987). Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc Natl Acad Sci U S A, Vol. 84, No. 22, (1987), pp 7957-61

Troyer, KL & Lee, DC (2001). Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia, Vol. 6, No. 1, (2001), pp 7-21

Tzahar, E, Waterman, H, Chen, X, Levkovitz, G, Karunagaran, D et al. (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol, Vol. 16, No. 10, (1996), pp 5276-87

van der Voort, R, Taher, TE, Wielenga, VJ, Spaargaren, M, Prevo, R et al. (1999). Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem, Vol. 274, No. 10, (1999), pp 6499-506

van Meer, G, Voelker, DR & Feigenson, GW (2008). Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol, Vol. 9, No. 2, (2008), pp 112-24

Vanoosten, RL, Moore, JM, Ludwig, AT & Griffith, TS (2005). Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther, Vol. 11, No. 4, (2005), pp 542-52

Veiseh, O, Gunn, JW, Kievit, FM, Sun, C, Fang, C et al. (2009). Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small, Vol. 5, No. 2, (2009), pp 256-64

Wan, J, Roth, AF, Bailey, AO & Davis, NG (2007). Palmitoylated proteins: purification and identification. Nat Protoc, Vol. 2, No. 7, (2007), pp 1573-84

Wang, B, Rosano, JM, Cheheltani, R, Achary, MP & Kiani, MF (2010). Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv, Vol. 7, No. 10, (2010), pp 1159-73

Wang, X, Wilson, MJ, Slaton, JW, Sinha, AA, Ewing, SL et al. (2009). Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP). J Androl, Vol. 30, No. 3, (2009), pp 259-74

Webb, Y, Hermida-Matsumoto, L & Resh, MD (2000). Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem, Vol. 275, No. 1, (2000), pp 261-70

Weinberg, OK, Marquez-Garban, DC & Pietras, RJ (2005). New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat, Vol. 8, No. 4, (2005), pp 219-33

Weroha, SJ & Haluska, P (2008). IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia, Vol. 13, No. 4, (2008), pp 471-83

Westover, EJ, Covey, DF, Brockman, HL, Brown, RE & Pike, LJ (2003). Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers. J Biol Chem, Vol. 278, No. 51, (2003), pp 51125-33

Worthylake, R, Opresko, LK & Wiley, HS (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem, Vol. 274, No. 13, (1999), pp 8865-74
Wysoczynski, M, Reca, R, Ratajczak, J, Kucia, M, Shirwaikar, N et al. (2005). Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. *Blood*, Vol. 105, No. 1, (2005), pp 40-8

Yamada, E (1955). The fine structure of the renal glomerulus of the mouse. *J Biophys Biochem Cytol*, Vol. 1, No. 6, (1955), pp 551-66

Yamaguchi, H, Takeo, Y, Yoshida, S, Kouchi, Z, Nakamura, Y et al. (2009). Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. *Cancer Res*, Vol. 69, No. 22, (2009), pp 8594-602

Yang, A, Wilson, NS & Ashkenazi, A (2010). Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. *Curr Opin Cell Biol*, Vol. 22, No. 6, (2010), pp 837-44

Yaqoob, P (2009). The nutritional significance of lipid rafts. *Annu Rev Nutr*, Vol. 29, No. (2009), pp 257-82
Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Irina S. Babina, Simona Donatello, Ivan R. Nabi and Ann M. Hopkins (2011). Lipid Rafts as Master Regulators of Breast Cancer Cell Function, Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, Prof. Mehmet Gunduz (Ed.), ISBN: 978-953-307-714-7, InTech, Available from: http://www.intechopen.com/books/breast-cancer-carcinogenesis-cell-growth-and-signalling-pathways/lipid-rafts-as-master-regulators-of-breast-cancer-cell-function